COSCIENS Biopharma Inc. (CSCI) Financial Statements

Income statement

Metric	TTM	2024	2023	2022	2021
Revenue
Total Revenue	9.4M	13.8M	7.1M	14.6M	13.5M
Cost of Revenue	5.0M	7.0M	4.2M	6.0M	5.3M
Gross Profit	4.3M	6.8M	2.9M	8.6M	8.2M
Operating Expenses
R&D Expense	7.5M	8.3M	2.0M	1.4M	3.0M
SG&A Expense	11.3M	10.4M	5.5M	2.9M	2.6M
General & Admin Expense	3.0M	10.4M	5.6M	2.7M	2.5M
Selling & Marketing Expense	—	—	30.5K	21.8K	37.0K
Other Expenses	4.3M	14.3M	—	—	162.3K
Total Operating Expenses	23.1M	33.1M	7.6M	4.2M	5.8M
Cost and Expenses	17.9M	40.1M	11.8M	10.3M	11.1M
Operating Income (EBIT)	(18.7M)	(26.3M)	(4.6M)	4.3M	2.4M
Non-Operating
Interest Income	617.2K	441.0K	59.0K	145.0K	—
Interest Expense	137.1K	129.0K	136.0K	143.0K	119.1K
Net Interest Income	480.1K	312.0K	(77.0K)	2.0K	(162.3K)
Other Non-Op Income/Expense	800.1K	11.1M	259.0K	208.0K	158.6K
Non-Operating Income (excl Interest)	(937.9K)	(12.0M)	(395.0K)	(351.0K)	(213.1K)
EBT (Pre-Tax Income)	(17.9M)	(15.2M)	(4.4M)	4.5M	2.6M
Income Tax Expense	971.0K	84.0K	(885.0K)	1.1M	(52.9K)
Bottom Line
Net Income	(18.8M)	(15.3M)	(3.5M)	3.4M	2.6M
Earnings from Cont. Ops	(18.8M)	(15.3M)	(3.5M)	3.4M	2.6M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(18.8M)	(15.3M)	(3.5M)	3.4M	2.6M
Per Share
Basic EPS	($6.21)	($5.93)	($1.89)	$2.51	$1.69
Diluted EPS	($6.21)	($5.93)	($1.89)	$2.50	$1.69
Revenue Per Share	$2.97	$5.34	$3.87	$7.92	$7.36
Shares
Basic Shares Outstanding	3.2M	2.6M	1.8M	1.8M	1.8M
Diluted Shares Outstanding	3.2M	2.6M	1.8M	1.9M	1.9M
Profitability Metrics
EBITDA	(16.2M)	(13.5M)	(2.8M)	6.1M	4.2M
D&A	1.5M	1.6M	1.4M	1.5M	1.5M
EBIT	(17.7M)	(15.1M)	(4.2M)	4.7M	2.7M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2025